Want to see AGIO full AI Analyst Report?
AGIO Stock Chart & Stats
$33.90
$0.08(0.22%)
At close: 4:00 PM EDT
$33.90
$0.08(0.22%)
Day’s Range― - ―
52-Week Range$22.24 - $46.00
Previous CloseN/A
Volume890.11K
Average Volume (3M)1.12M
Market Cap
$2.19B
Enterprise Value$1.62B
Total Cash (Recent Filing)$617.58M
Total Debt (Recent Filing)$31.17M
Price to Earnings (P/E)―
Beta1.86
Next Earnings
Nov 05, 2026EPS Estimate
-1.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-7.01
Shares Outstanding59,701,880
10 Day Avg. Volume1,358,721
30 Day Avg. Volume1,115,253
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)1.32
Price to Sales (P/S)29.21
P/FCF Ratio-4.18
Enterprise Value/Market Cap0.74
Enterprise Value/Revenue16.49
Enterprise Value/Gross Profit18.75
Enterprise Value/Ebitda-3.89
Forecast
1Y Price Target
$45.20Price Target Upside33.33% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.75
Revenue Forecast (FY)$178.00M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Gross MarginStrong revenue growth alongside an approximately 82% gross margin indicates improving product and royalty economics. If commercial adoption continues, this combination can provide meaningful operating leverage and support a more durable earnings base as the business scales.
Low Financial LeverageVery low leverage gives Agios financial flexibility while it funds commercialization and clinical development. A substantial asset base and limited debt burden reduce dependence on borrowing and improve the company’s ability to sustain strategic investment.
Commercial Launch TractionGrowing prescriptions and broad payer coverage provide evidence that AQVESME is gaining commercial access in its target market. Continued treatment conversion and reimbursement support could make product revenue increasingly important to the company’s longer-term growth.
Bears Say
Persistent Cash BurnHeavy operating and free cash outflows show that Agios is not yet funding its activities from internally generated cash. Continued burn could require sustained use of its capital base until commercial growth and operating leverage materially reduce losses.
Deep Operating LossesThe scale of current operating losses remains a significant fundamental weakness despite strong revenue growth. Achieving durable profitability will depend on converting commercial expansion into sufficient gross profit to absorb substantial research and corporate expenses.
Revenue And Rebate PressureReported revenue may be uneven because stocking effects and order timing can distort quarterly demand, while higher Medicaid exposure may reduce realized sickle cell revenue. These factors could make growth and margin progression less predictable during expansion.
Agios Pharma News
AGIO FAQ
What was Agios Pharma’s price range in the past 12 months?
Agios Pharma lowest stock price was $22.24 and its highest was $46.00 in the past 12 months.
What is Agios Pharma’s market cap?
Agios Pharma’s market cap is $2.19B.
When is Agios Pharma’s upcoming earnings report date?
Agios Pharma’s upcoming earnings report date is Nov 05, 2026 which is in 14 days.
How were Agios Pharma’s earnings last quarter?
Agios Pharma released its earnings results on Jul 30, 2026. The company reported -$1.69 earnings per share for the quarter, missing the consensus estimate of -$1.655 by -$0.035.
Is Agios Pharma overvalued?
According to Wall Street analysts Agios Pharma’s price is currently Undervalued.
Does Agios Pharma pay dividends?
Agios Pharma does not currently pay dividends.
What is Agios Pharma’s EPS estimate?
Agios Pharma’s EPS estimate is -1.25.
How many shares outstanding does Agios Pharma have?
Agios Pharma has 59,701,880 shares outstanding.
What happened to Agios Pharma’s price movement after its last earnings report?
Agios Pharma reported an EPS of -$1.69 in its last earnings report, missing expectations of -$1.655. Following the earnings report the stock price went down -6.455%.
Which hedge fund is a major shareholder of Agios Pharma?
Currently, no hedge funds are holding shares in AGIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Agios Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$45.20 (33.33% Upside)
$45.20 (33.33% Upside)
Blogger Sentiment
Bullish
AGIO Sentiment 100%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 159.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▲ 2.5%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.43%
12-Months-Change
Fundamentals
Return on Equity
-35.67%
Trailing 12-Months
Asset Growth
-24.66%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Agios Pharma
Agios Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to the research and advancement of new treatments, specifically targeting cellular metabolism and related biological fields. The company's offerings include PYRUKYND (mitapivat), a medication designed to activate both wild-type and various mutated pyruvate kinase (PK) enzymes, used in the management of hemolytic anemias. Additionally, Agios is developing AG-946, which is currently undergoing Phase I clinical studies for treating hemolytic anemias and other diseases. Established in 2007, the company's main office is located in Cambridge, Massachusetts.
AGIO Company Deck
AGIO Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated substantial commercial momentum (AQVESME launch traction and U.S.-centric revenue), a meaningful near-term regulatory catalyst (Mitapivat PDUFA on Nov 1), and active pipeline expansion (cevidoplenib, AG-236, AG-181), supported by a strong cash position (~$1B). Offsetting these positives are elevated R&D and SG&A spending, a sizable net loss ($100.7M), quarter-to-quarter revenue variability (including a one-time $5M stocking benefit in Q2), and potential pricing/net revenue pressures for a sickle cell indication due to higher Medicaid mix and rebates. On balance, the operational and pipeline progress and the regulatory catalyst outweigh the financial and visibility challenges.View all AGIO earnings summariesAGIO Stock 12 Month Forecast
Average Price Target
$45.20
▲(33.33% Upside)
Technical Analysis
Ultragenyx Pharmaceutical
―
Iovance Biotherapeutics
―
Intellia Therapeutics
―
Beam Therapeutics
―
Nurix Therapeutics
―
Ownership Overview
1.11% Insiders
26.25% Mutual Funds
3.27% Other Institutional Investors
48.23% Public Companies and
Individual Investors